Trials / Not Yet Recruiting
Not Yet RecruitingNCT07449156
A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris.
A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of HB0043 (Bispecific Antibody Targeting IL-17A and IL-36R) in Adult Patients With Moderate to Severe Acne Vulgaris (AV).
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe AV.
Detailed description
The total duration of the study is 18 weeks and consists of: Screening (up to 2 weeks) and Treatment Period (16 weeks).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HB0043 | 300mg |
| DRUG | Placebo | 300mg |
Timeline
- Start date
- 2026-03-27
- Primary completion
- 2026-10-27
- Completion
- 2027-03-27
- First posted
- 2026-03-04
- Last updated
- 2026-03-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07449156. Inclusion in this directory is not an endorsement.